A “Round 2” edition of biotech highlights:
- Round 1 of this week’s IPOs (yep, that’s IPO with an “s”, as in more than one) was a draw, with shares of Cumberland ending flat on the day [1]; but Round 2 — Emdeon’s offering the next day — was a knock-out, leading some (ok, me) to suggest the markets may be opening up [2] to the idea of biopharma offerings.
- Round 2 of Amgen’s study showed that genetic differences really do correlate with response to their medicine [3] — Vectibix — in the treatment of colorectal cancer. Score this one for personalized medicine [4].
and last but not least:
- Round 2 of Richard Chan’s new and improved Friday Science Review [5] was posted on the blog, with great items on MS, Epilepsy and DNA forensics.
Although I boxed myself in (har) and can’t fit it into the post’s theme, please check out the new mentoring program that I’ve been helping to plan [6], along with all the other good things that happen when the gloves come off at the Cross-Border Biotech Blog [7].